Market Place
Sourcing Support
ReiThera, SillaJen Partner On SJ-600 Clinical Trial Development
24 Jan 2025 //
CONTRACTPHARMA
OSR, SillaJen MOU For US Therapeutic Development
22 Apr 2024 //
PR NEWSWIRE
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
27 Mar 2024 //
BUSINESSWIRE
SillaJen to acquire rights for Basilea’s novel kinase inhibitor, BAL0891
21 Sep 2022 //
PHARMABIZ
Basilea announces acquisition of rights for oncology asset BAL0891
19 Sep 2022 //
GLOBENEWSWIRE
SillaJen CEO detained over alleged insider trading, stoking fears of delisting
12 May 2020 //
THEINVESTOE
HiFiBiO`s Kite-backed C round; Kyowa Kirin`s Parkinson`s nod; Relief for Sun
30 Aug 2019 //
FIERCE PHARMA
Bain`s Orly Mishan joins Pfizer`s neuro spinout Cerevel
17 Aug 2019 //
ENDPTS
Transgene terminates oncolytic IO combo trial in advanced liver cancer
08 Aug 2019 //
PHARMAFILE
SillaJen to discontinue PHOCUS trial for advanced liver cancer
05 Aug 2019 //
BIOSPECTRUMASIA
Phase 3 trial of Transgene`s oncolytic virus halted for futility
03 Aug 2019 //
FIERCE BIOTECH
SillaJen reveals clinical results on Pexa-Vec in UK
13 Apr 2018 //
KOREABIOMED
SillaJen & ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic
22 Jan 2018 //
PR NEWSWIRE
SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec
29 Mar 2016 //
PR NEWSWIRE
Medivate Partners Invests $12 Million in Sillajen
22 Mar 2016 //
PR NEWSWIRE
SillaJen Announces First Patient Randomized in Ph3 Trial for Pexa-Vec
05 Jan 2016 //
PR NEWS WIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.